Randomized Clinical Trial of Long-Acting Oxytetracycline, Foot Trimming, and Flunixine Meglumine on Time to Recovery in Sheep with Footrot

被引:74
|
作者
Kaler, J. [1 ]
Daniels, S. L. S. [1 ]
Wright, J. L. [1 ]
Green, L. E. [1 ]
机构
[1] Univ Warwick, Dept Biol Sci, Coventry CV4 7AL, W Midlands, England
基金
英国生物技术与生命科学研究理事会;
关键词
Antibacterials; Dichelobacter nodosus; Infectious disease; Ovine; VIRULENT FOOTROT; OVINE; LAMENESS; RECOGNITION; MANAGEMENT;
D O I
10.1111/j.1939-1676.2009.0450.x
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
Background Internationally, foot trimming is used by most farmers, and parenteral antibacterials by some, to treat sheep with footrot. Nonsteroidal anti-inflammatory drugs (NSAID) are sometimes used. No clinical trials have compared these treatments. Objectives To investigate the above treatments on time to recovery from lameness and foot lesions in sheep with footrot. Animals Fifty-three sheep with footrot on a commercial farm in England. Methods In a randomized factorial design, the sheep were allocated to 6 treatment groups. The treatments were oxytetracycline spray to all sheep (positive control) and one or more of parenteral administration of long-acting oxytetracycline, flunixine meglumine, and foot trimming on day 1 or 6 of diagnosis. Follow-up was for 15 days. Time to recovery from lameness and lesions was investigated with discrete-time survival models. Results There was significant association (P < .05) between recovery from lameness and lesions. Sheep receiving antibacterials parenterally recovered faster from lameness (odds ratio [OR]: 4.92 [1.20-20.10]) and lesions (OR: 5.11 [1.16-22.4]) than positive controls, whereas sheep foot trimmed on day 1 (lameness-OR: 0.05 [0.005-0.51]; lesions-OR: 0.06 [0.008-0.45]) or day 6 of diagnosis (lameness-OR: 0.07 [0.01-0.72]; lesions-OR: 0.07 [0.01-0.56]) recovered more slowly than positive controls. NSAID had no significant effect on recovery. Conclusions and Clinical Importance If foot trimming on day 1 or 6 of diagnosis was stopped and parenteral antibacterials were used, then over 1 million sheep/annum lame with footrot in the United Kingdom would recover more rapidly with benefits to productivity. Globally, this figure would be much higher.
引用
收藏
页码:420 / 425
页数:6
相关论文
共 48 条
  • [21] Relapse Prevention in Schizophrenia and Schizoaffective Disorder with Risperidone Long-Acting Injectable vs Quetiapine: Results of a Long-Term, Open-Label, Randomized Clinical Trial
    Wolfgang Gaebel
    Andreas Schreiner
    Paul Bergmans
    Rosario de Arce
    Frédéric Rouillon
    Joachim Cordes
    Lars Eriksson
    Enrico Smeraldi
    Neuropsychopharmacology, 2010, 35 : 2367 - 2377
  • [22] Pansomatostatin Agonist Pasireotide Long-Acting Release for Patients with Autosomal Dominant Polycystic Kidney or Liver Disease with Severe Liver Involvement A Randomized Clinical Trial
    Hogan, Marie C.
    Chamberlin, Julie A.
    Vaughan, Lisa E.
    Waits, Angela L.
    Banks, Carly
    Leistikow, Kathleen
    Oftsie, Troy
    Madsen, Chuck
    Edwards, Marie
    Glockner, James
    Kremers, Walter K.
    Harris, Peter C.
    LaRusso, Nicholas F.
    Torres, Vicente E.
    Masyuk, Tatyana V.
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2020, 15 (09): : 1267 - 1278
  • [23] RELAPSE PREVENTION IN SCHIZOPHRENIA AND SCHIZOAFFECTIVE DISORDER WITH RISPERIDONE LONG-ACTING INJECTABLE VERSUS QUETIAPINE: RANDOMIZED, LONG-TERM, OPEN-LABEL, CLINICAL TRIAL RESULTS (CONSTATRE)
    Gaebel, W.
    Bergmans, P.
    de Arce, R.
    Rouillon, F.
    Cordes, J.
    Eriksson, L.
    Schreiner, A.
    Smeraldi, E.
    EUROPEAN PSYCHIATRY, 2009, 24
  • [24] Erratum: Relapse Prevention in Schizophrenia and Schizoaffective Disorder with Risperidone Long-Acting Injectable vs Quetiapine: Results of a Long-Term, Open-Label, Randomized Clinical Trial
    Wolfgang Gaebel
    Andreas Schreiner
    Paul Bergmans
    Rosario de Arce
    Frédéric Rouillon
    Joachim Cordes
    Lars Eriksson
    Enrico Smeraldi
    Neuropsychopharmacology, 2011, 36 : 548 - 548
  • [25] Effect of Long-Acting Injectable Antipsychotics vs Usual Care on Time to First Hospitalization in Early-Phase Schizophrenia: A Randomized Clinical Trial (Jul, 10.1001/jamapsychiatry.2020.2076, 2020)
    Kane, J. M.
    Schooler, N. R.
    Marcy, P.
    JAMA PSYCHIATRY, 2020, 77 (12) : 1310 - 1310
  • [26] A randomized clinical trial of the effect of intensive versus non-intensive counselling on discontinuation rates due to bleeding disturbances of three long-acting reversible contraceptives
    Modesto, Waleska
    Valeria Bahamondes, M.
    Bahamondes, Luis
    HUMAN REPRODUCTION, 2014, 29 (07) : 1393 - 1399
  • [27] Recombinant long-acting glycopegylated factor IX (nonacog beta pegol) in hemophilia B: assessment of target joints in the multinational randomized phase 3 clinical trial
    Negrier, C.
    Karim, F. A.
    Hanabusa, H.
    Collins, P.
    Colberg, T.
    Goldman, B.
    Walsh, C.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : 316 - 316
  • [28] Onset of efficacy and tolerability following the initiation dosing of long-acting paliperidone palmitate: post-hoc analyses of a randomized, double-blind clinical trial
    Bossie, Cynthia A.
    Sliwa, Jennifer K.
    Ma, Yi-Wen
    Fu, Dong-Jing
    Alphs, Larry
    BMC PSYCHIATRY, 2011, 11
  • [29] Onset of efficacy and tolerability following the initiation dosing of long-acting paliperidone palmitate: post-hoc analyses of a randomized, double-blind clinical trial
    Cynthia A Bossie
    Jennifer K Sliwa
    Yi-Wen Ma
    Dong-Jing Fu
    Larry Alphs
    BMC Psychiatry, 11
  • [30] Long-acting injectable methadone (methadone-fluconazole) provides safe and effective postoperative analgesia in a randomized clinical trial for dogs undergoing soft tissue surgery
    Bieberly, Zackery D.
    KuKanich, Butch
    KuKanich, Kate S.
    Berke, Kara A.
    Klocke, Emily E.
    Upchurch, David A.
    Comroe, Alyssa J.
    Jugan, Maria C.
    Mason, Diane E.
    Orchard, Ron J.
    Klutzke, Joshuah B.
    Fitzgerald, Alyson H.
    Woodruff, Kallie
    AMERICAN JOURNAL OF VETERINARY RESEARCH, 2022, 83 (08)